Mayo Clinic
Investigatores in Campo Mayo Clinic Floridae quinquennium foederati praestationem totaling $13 miliones ad experimentum vaccinorum rettulerunt, ne recursus cancri pectoris triplo-negativo impediret. Triplex cancer pectus negativum est species valde maligni carcinomatis carcinomatis, et in praesenti curatio iaculis nulla est.
280 Aegri hoc iudicium clinicum participabunt, quod primo 2016 incepit.
The funding is a breakthrough award from the U.S. Department of Defense’s Breast Cancer Research Project and will be used to fund a nationwide phase II clinical trial to test the receptor folate alpha vaccine ne is maxime malignus tumor post curationem recurrat.
Phase I iudicium clinicum implicans XXII aegros ante Keith Knutson, PhD in immunologia, vaccinum tutum invenit. Autoimmunitatem non inducit.
Vaccinum a Dr. Knutson designatum est et ab investigatoribus Mayo Clinic Rochester campus Mayo initio probatus est ad experimentum salutis et facultatem ad systema immunem incitandum.
It takes advantage of the characteristics of triple negative pectus cancer that require folic acid intake. Dr. Knutson said that because of this need, these tumors synthesize a large amount of folate receptor alpha, which is used to latch folic acid into the tumor’s microenvironment.
Testantur aliquos aegros naturaliter receptoribus immunem responsionem evolvere. "Sed cancer fortior est ad hanc responsionem immunem infirmam," Dr. Knutson dixit.
The purpose of the vaccine is to promote the immune system to respond quickly to cancer cell receptors during the early stages of tuberculum recursu.
Dixit, "Credimus vaccinum validiorem et diuturnam responsionem immunem praestaturum recipienti, quod vicissim facultatem corporis obtinebit ut acidum folicum abscissione tumoris incidat et tumorem directe vel indirecte interficiat."
